10.13
0.11 (1.10%)
| Previous Close | 10.02 |
| Open | 9.71 |
| Volume | 255,286 |
| Avg. Volume (3M) | 595,431 |
| Market Cap | 492,198,464 |
| Price / Sales | 8.11 |
| Price / Book | 5.53 |
| 52 Weeks Range |
| Diluted EPS (TTM) | -6.04 |
| Quarterly Revenue Growth (YOY) | -100.00% |
| Total Debt/Equity (MRQ) | 8.29% |
| Current Ratio (MRQ) | 13.93 |
| Operating Cash Flow (TTM) | -59.79 M |
| Levered Free Cash Flow (TTM) | -36.41 M |
| Return on Assets (TTM) | -33.29% |
| Return on Equity (TTM) | -68.14% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Artiva Biotherapeutics, Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | 3.5 |
| Price Volatility | -3.5 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 4.0 |
| Average | 0.38 |
|
Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials. The company pipeline includes AlloNK: is an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of mAbs to drive B-cell. Others products includes: CAR-NK(AB201),CAR-NK(AB205). |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 19.99% |
| % Held by Institutions | 89.73% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Revelation Capital Management, Llc | 31 Mar 2026 | 299,311 |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 9.24 | - | 166,906 | 1,513,785 |
| Aggregate Net Quantity | 166,906 | |||
| Aggregate Net Value ($) | 1,513,785 | |||
| Aggregate Avg. Buy ($) | 9.24 | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | Director | 17 Jul 2026 | Buy (+) | 7,882 | 9.76 | 76,928 |
| RA CAPITAL MANAGEMENT, L.P. | Director | 16 Jul 2026 | Buy (+) | 152,472 | 9.04 | 1,378,347 |
| RA CAPITAL MANAGEMENT, L.P. | Director | 13 Jul 2026 | Buy (+) | 6,552 | 8.93 | 58,509 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |